Evidence has implicated multiple downstream targets of β-catenin in kidney injury and fibrotic CKD, including matrix metalloproteinase-7 (MMP-7) and plasminogen activator inhibitor-1 (PAI-1) [91]. Here, MMP7 is linked to chronic kidney disease.